DENTSPLY SIRONA (NASDAQ:XRAY) Director James Forbes Purchases 5,000 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director James Forbes acquired 5,000 shares of the stock in a transaction dated Monday, March 9th. The stock was acquired at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ XRAY opened at $12.80 on Tuesday. DENTSPLY SIRONA Inc. has a 12-month low of $9.85 and a 12-month high of $17.18. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -4.27, a price-to-earnings-growth ratio of 1.49 and a beta of 0.97. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. The firm has a 50 day moving average of $12.66 and a 200 day moving average of $12.44.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 5.0%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently -21.33%.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several large investors have recently made changes to their positions in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DENTSPLY SIRONA during the 1st quarter valued at approximately $26,000. Goldman Sachs Group Inc. raised its holdings in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after acquiring an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after acquiring an additional 41,579 shares during the last quarter. Finally, Focus Partners Wealth grew its holdings in shares of DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on XRAY. UBS Group cut their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Barrington Research lifted their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Barclays started coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price for the company. Finally, Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Three analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.